• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织芯片技术在卵巢癌中的验证

Validation of tissue microarray technology in ovarian carcinoma.

作者信息

Rosen Daniel G, Huang Xuelin, Deavers Michael T, Malpica Anais, Silva Elvio G, Liu Jinsong

机构信息

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4095, USA.

出版信息

Mod Pathol. 2004 Jul;17(7):790-7. doi: 10.1038/modpathol.3800120.

DOI:10.1038/modpathol.3800120
PMID:15073602
Abstract

High-throughput tissue microarray allows many clinical specimens to be analyzed simultaneously on a single slide. One potential limitation of tissue microarray is the correct representation of each tumor with the small tissue core. Because tumors from different organs have different levels of heterogeneity, it requires a validation study for each one of them. We compared immunostaining of Ki-67, estrogen receptors, and p53 in whole sections of 45 cases of high-grade serous ovarian carcinoma with six core samples from those sections with regard to the number of tissue cores needed to reliably represent a whole section. Staining for Ki-67 was graded high or low by automated image analysis of 10 high-power fields; staining for estrogen receptor and p53 was scored on a 0-to-3 scale. Correlation coefficients for whole-section vs core stains were 0.86 for Ki-67, 0.93 for estrogen receptors, and 0.82 for p53. A total of 54 (6.6%) of the cores were inadequate for scoring. The probability that results from one core would correctly represent all three markers in the whole section was 91%; that for two cores was 96%; and that for three cores was 98%. Our results show that analysis of a single readable core matched the staining pattern of a whole section more than 90% of the time, and analysis of two cores increased that value to more than 95%, demonstrating that ovarian carcinoma tissue microarray is a reliable technique to analyze the expression of markers.

摘要

高通量组织芯片可在一张载玻片上同时对多个临床标本进行分析。组织芯片的一个潜在局限性在于,小组织芯能否正确代表每个肿瘤。由于来自不同器官的肿瘤具有不同程度的异质性,因此每个肿瘤都需要进行验证研究。我们比较了45例高级别浆液性卵巢癌全切片中Ki-67、雌激素受体和p53的免疫染色情况,以及这些切片中的六个芯样,以确定可靠代表整个切片所需的组织芯数量。通过对10个高倍视野进行自动图像分析,将Ki-67染色分为高或低;雌激素受体和p53染色按0至3分进行评分。全切片与芯样染色的相关系数分别为:Ki-67为0.86,雌激素受体为0.93,p53为0.82。共有54个(6.6%)芯样评分不足。一个芯样的结果能正确代表全切片中所有三种标志物的概率为91%;两个芯样的概率为96%;三个芯样的概率为98%。我们的结果表明,对单个可读芯样的分析在超过90%的情况下与全切片的染色模式相符,对两个芯样的分析将这一比例提高到超过95%,这表明卵巢癌组织芯片是一种分析标志物表达的可靠技术。

相似文献

1
Validation of tissue microarray technology in ovarian carcinoma.组织芯片技术在卵巢癌中的验证
Mod Pathol. 2004 Jul;17(7):790-7. doi: 10.1038/modpathol.3800120.
2
Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer.组织芯片技术在直肠癌免疫组织化学分析中的应用评价
Arch Pathol Lab Med. 2002 Jun;126(6):702-5. doi: 10.5858/2002-126-0702-EOTTMT.
3
An immunohistochemical analysis of sex-steroid receptors, tumor suppressor gene p53 and Ki-67 in the normal and neoplastic uterine cervix squamous epithelium.正常及肿瘤性子宫颈鳞状上皮中性激素受体、肿瘤抑制基因p53和Ki-67的免疫组织化学分析
Med Pregl. 2014 Jul-Aug;67(7-8):202-7. doi: 10.2298/mpns1408202n.
4
Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.交界性浆液性卵巢肿瘤与晚期浆液性乳头状卵巢癌的临床及分子比较
Eur J Gynaecol Oncol. 2001;22(4):292-6.
5
[Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].[低级别和高级别卵巢浆液性癌中Pax2、p53和Ki-67的临床病理研究及免疫组化比较]
Zhonghua Bing Li Xue Za Zhi. 2011 Aug;40(8):511-6.
6
Tissue microarray validation: a methodologic study with special reference to lung cancer.组织芯片验证:一项特别针对肺癌的方法学研究
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2014-21. doi: 10.1158/1055-9965.EPI-08-0743. Epub 2009 Jun 16.
7
P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.p53、MAPK、拓扑异构酶 IIα 和 Ki67 的免疫组化表达与卵巢浆液性癌的 KRAS/BRAF 突变。
Diagn Pathol. 2013 Feb 6;8:21. doi: 10.1186/1746-1596-8-21.
8
Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques.提高福尔马林固定石蜡切片中各种核内预后标志物免疫组化染色的策略:通过抗原修复技术显示雄激素受体、雌激素受体、孕激素受体、p53蛋白、增殖细胞核抗原和Ki-67抗原。
Hum Pathol. 1994 Mar;25(3):263-70. doi: 10.1016/0046-8177(94)90198-8.
9
[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].[PAX8、PAX2、p53和RAS在卵巢及输卵管中的表达及其对卵巢高级别浆液性癌起源的意义]
Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008.
10
Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology.p53蛋白表达及Ki-67反应性在卵巢肿瘤中的情况。与组织病理学的相关性。
Am J Clin Pathol. 1996 Mar;105(3):334-40. doi: 10.1093/ajcp/105.3.334.

引用本文的文献

1
Clinical significance of CD166 and HER-2 in different types of gastric cancer.CD166 和 HER-2 在不同类型胃癌中的临床意义。
Clin Transl Oncol. 2024 Mar;26(3):664-681. doi: 10.1007/s12094-023-03297-0. Epub 2023 Aug 3.
2
Oestrogen receptor low positive breast cancer: associations with prognosis.雌激素受体低表达阳性乳腺癌:与预后的关系。
Breast Cancer Res Treat. 2023 Oct;201(3):535-545. doi: 10.1007/s10549-023-07040-9. Epub 2023 Jul 18.
3
Postoperative Prognostic Predictors of Bile Duct Cancers: Clinical Analysis and Immunoassays of Tissue Microarrays.
胆管癌的术后预后预测因子:组织微阵列的临床分析和免疫测定。
Gut Liver. 2023 Jan 15;17(1):159-169. doi: 10.5009/gnl220044. Epub 2022 Nov 1.
4
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.Movember 全球行动计划 1(GAP1):独特的前列腺癌组织微阵列资源。
Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):715-727. doi: 10.1158/1055-9965.EPI-21-0600.
5
High expression of DNA damage-inducible transcript 4 (DDIT4) is associated with advanced pathological features in the patients with colorectal cancer.DNA 损伤诱导转录物 4(DDIT4)的高表达与结直肠癌患者的晚期病理特征相关。
Sci Rep. 2021 Jul 1;11(1):13626. doi: 10.1038/s41598-021-92720-z.
6
Immune Cell Infiltrate and Prognosis in Gastric Cancer.胃癌中的免疫细胞浸润与预后
Cancers (Basel). 2020 Dec 2;12(12):3604. doi: 10.3390/cancers12123604.
7
Protein expression profiles and clinicopathologic characteristics associate with gastric cancer survival.蛋白表达谱与临床病理特征与胃癌生存相关。
Biol Res. 2019 Aug 9;52(1):42. doi: 10.1186/s40659-019-0249-0.
8
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.一种多生物标志物面板分析,以更好地预测根治性前列腺切除术后前列腺癌转移。
Int J Cancer. 2019 Mar 1;144(5):1151-1159. doi: 10.1002/ijc.31906. Epub 2018 Dec 4.
9
B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.B7-H4在卵巢浆液性癌中的表达:306例研究
Hum Pathol. 2016 Nov;57:1-6. doi: 10.1016/j.humpath.2016.06.011. Epub 2016 Jun 24.
10
Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays.使用异质性组织微阵列测定结直肠癌中的肿瘤异质性
Pathol Oncol Res. 2015 Sep;21(4):1183-9. doi: 10.1007/s12253-015-9953-4. Epub 2015 May 31.